KRAS Mutation Analysis by PCR: A Comparison of Two Methods

Background KRASmutation assays are important companion diagnostictests to guide anti-EGFR antibody treatment of metastatic colorectal cancer. Direct comparison of newer diagnostic methods with existing methods is an important part of validation of any new technique. In this this study, we have compared the Therascreen (Qiagen) ARMS assay with Competitive Allele-Specific TaqManPCR (castPCR, Life Technologies) to determine equivalence for KRASmutation analysis. Methods